"Nuclear medicines, like radioligand therapy, could be transformative for cancer care in Australia. Establishing clear pathways for market access and a thriving nuclear medicine industry will be key to enabling Australian patients to access these new treatment options," said Novartis country president Matt Zeller.
New Novartis-backed report identifies nuclear medicine opportunity but calls for change
April 19, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Podcast - Special episode
June 5, 2026 - - Podcast -
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News -
A clear disconnect between the public and private on 'Most Favored Nation' pricing
June 5, 2026 - - Latest News -
New blueprint charts a potential policy path forward on biosimilars
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News

